C5 Complement Inhibitors Market Size to Hit USD 16.01 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on C5 Complement Inhibitors Market

5.1. COVID-19 Landscape: C5 Complement Inhibitors Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global C5 Complement Inhibitors Market, By Drug Type

8.1. C5 Complement Inhibitors Market Revenue and Volume, by Drug Type

8.1.1. Monoclonal Antibodies

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Small Molecule Inhibitors

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. RNA-based Therapeutics

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Peptide-based Inhibitors

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global C5 Complement Inhibitors Market, By Route of Administration

9.1. C5 Complement Inhibitors Market Revenue and Volume, by Route of Administration

9.1.1. Intravenous

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Subcutaneous

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Oral

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global C5 Complement Inhibitors Market, By Application / Indication

10.1. C5 Complement Inhibitors Market Revenue and Volume, by Application / Indication

10.1.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Atypical Hemolytic Uremic Syndrome (aHUS)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Neuromyelitis Optica Spectrum Disorder (NMOSD)

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Myasthenia Gravis

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Other Rare Diseases

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global C5 Complement Inhibitors Market, By End User

11.1. C5 Complement Inhibitors Market Revenue and Volume, by End User

11.1.1. Hospitals

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Specialty Clinics

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Research & Academic Institutes

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Homecare

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global C5 Complement Inhibitors Market, By Distribution Channel

12.1. C5 Complement Inhibitors Market Revenue and Volume, by Distribution Channel

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Retail Pharmacies

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Specialty Pharmacies

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Online Pharmacies

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global C5 Complement Inhibitors Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type

13.1.2. Market Revenue and Volume Forecast, by Route of Administration

13.1.3. Market Revenue and Volume Forecast, by Application / Indication

13.1.4. Market Revenue and Volume Forecast, by End User

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type

13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.3. Market Revenue and Volume Forecast, by Application / Indication

13.1.6.4. Market Revenue and Volume Forecast, by End User

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type

13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.3. Market Revenue and Volume Forecast, by Application / Indication

13.1.7.4. Market Revenue and Volume Forecast, by End User

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type

13.2.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.3. Market Revenue and Volume Forecast, by Application / Indication

13.2.4. Market Revenue and Volume Forecast, by End User

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type

13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.6.3. Market Revenue and Volume Forecast, by Application / Indication

13.2.7. Market Revenue and Volume Forecast, by End User

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type

13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.9.3. Market Revenue and Volume Forecast, by Application / Indication

13.2.10. Market Revenue and Volume Forecast, by End User

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type

13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.12.3. Market Revenue and Volume Forecast, by Application / Indication

13.2.12.4. Market Revenue and Volume Forecast, by End User

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type

13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.14.3. Market Revenue and Volume Forecast, by Application / Indication

13.2.14.4. Market Revenue and Volume Forecast, by End User

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type

13.3.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.3. Market Revenue and Volume Forecast, by Application / Indication

13.3.4. Market Revenue and Volume Forecast, by End User

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type

13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.6.3. Market Revenue and Volume Forecast, by Application / Indication

13.3.6.4. Market Revenue and Volume Forecast, by End User

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type

13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.8.3. Market Revenue and Volume Forecast, by Application / Indication

13.3.8.4. Market Revenue and Volume Forecast, by End User

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type

13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.3. Market Revenue and Volume Forecast, by Application / Indication

13.3.10.4. Market Revenue and Volume Forecast, by End User

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type

13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.3. Market Revenue and Volume Forecast, by Application / Indication

13.3.11.4. Market Revenue and Volume Forecast, by End User

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type

13.4.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.3. Market Revenue and Volume Forecast, by Application / Indication

13.4.4. Market Revenue and Volume Forecast, by End User

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type

13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.6.3. Market Revenue and Volume Forecast, by Application / Indication

13.4.6.4. Market Revenue and Volume Forecast, by End User

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type

13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.8.3. Market Revenue and Volume Forecast, by Application / Indication

13.4.8.4. Market Revenue and Volume Forecast, by End User

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type

13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.3. Market Revenue and Volume Forecast, by Application / Indication

13.4.10.4. Market Revenue and Volume Forecast, by End User

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type

13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.3. Market Revenue and Volume Forecast, by Application / Indication

13.4.11.4. Market Revenue and Volume Forecast, by End User

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type

13.5.2. Market Revenue and Volume Forecast, by Route of Administration

13.5.3. Market Revenue and Volume Forecast, by Application / Indication

13.5.4. Market Revenue and Volume Forecast, by End User

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type

13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.5.6.3. Market Revenue and Volume Forecast, by Application / Indication

13.5.6.4. Market Revenue and Volume Forecast, by End User

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type

13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.3. Market Revenue and Volume Forecast, by Application / Indication

13.5.8.4. Market Revenue and Volume Forecast, by End User

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Amgen Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. UCB Pharma,

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Horizon Therapeutics

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Roche Glycart,

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Omeros Corporation,

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. IONIS Pharmaceuticals

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Akari Therapeutic

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Morphosys AG

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Annexon Biosciences

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Novartis AG

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The C5 complement inhibitors market size is expected to increase from USD 4.25 billion in 2024 to USD 16.01 billion by 2034.

The C5 complement inhibitors market is expected to grow at a compound annual growth rate (CAGR) of around 14.18% from 2025 to 2034.

The major players in the C5 complement inhibitors market include Alexion Pharmaceuticals, Roche, Novartis AG, Apellis Pharmaceuticals, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Amgen Inc., UCB Pharma, Biogen Inc., Johnson & Johnson (Janssen), Takeda Pharmaceutical Company, Horizon Therapeutics, Silence Therapeutics, Ra Pharmaceuticals, Roche Glycart, Omeros Corporation, IONIS Pharmaceuticals, Akari Therapeutics, Annexon Biosciences, Morphosys AG

The driving factors of the C5 complement inhibitors market are the increased rate of rare and fatal diseases that need C5 inhibitor-based treatment, growing research and development in developed countries for innovative inhibitors, and advancement in the biotechnology area.

North America region will lead the global C5 complement inhibitors market during the forecast period 2025 to 2034.